Taysha Gene Therapies (TSHA) Common Equity (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Common Equity data on file, last reported at $211.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 284.94% year-over-year to $211.9 million; the trailing twelve-month figure through Mar 2026 stood at $211.9 million (up 284.94% YoY), and the FY2025 full-year result was $246.9 million, up 245.25% from the prior year.
• Common Equity eased to $211.9 million in Q1 2026, from $246.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $248.7 million in Q2 2025 to a low of -$49.1 million in Q3 2023.
• A 5-year average of $80.8 million and a median of $55.1 million in 2025 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 7796.42% in 2023, while the deepest fall reached 558.88% in 2023.
• Tracing TSHA's Common Equity over 5 years: stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then declined by 4.55% to $71.5 million in 2024, then surged by 245.25% to $246.9 million in 2025, then slipped by 14.17% to $211.9 million in 2026.
• Business Quant data shows TSHA's Common Equity at $211.9 million in Q1 2026, $246.9 million in Q4 2025, and $219.0 million in Q3 2025.